Saturday 17 October 2026 Export FBIO’s income statement to Excel — free account

Fortress Biotech, Inc.

Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024. In the quarter to June 2026, revenue grew 14.0%, EPS fell 116.0%, free cash flow fell 115.4% and total debt fell 35.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.87 0.04 −2.09%

Follow FBIO

Alert me

Market cap: $63.7M
P/E: 0.6×
Fwd P/E: 1.1×
Dividend yield: —
F-score: 5/9
Altman Z: −5.47
Beneish M: −0.01
Dividend safety: 20/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 27.53%

Capital & Financial Ratios $m

Market Cap 63.70

Revenue 68.47

Net Income 141.19

Free Cash Flow 125.84

Net Debt (161.97)

Current Ratio 3.96

Debt/Equity 0.17

P/E ratio 0.57

Fwd P/E 1.10

P/S ratio 0.87

P/B ratio 0.29

Past 5Y EPS Growth —

This Y EPS Growth 3,742.86%

Next Y EPS Growth (139.22%)

Next Y revenue growth 24.55%

Next 5Y EPS Growth 9.86%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 22.32%

10-year low 10-year high

P/B against its own 10 years 0.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	81	57	79	197
Receivables	15	10	30	37
Inventory	10	14	10	8
Other	—	1	—	—
	117	90	124	246

	2023	2024	2025	Q'26
Payables	74	66	47	49
ST’ Debt	—	—	—	—
Other	5	2	0	0
	85	71	50	62

Compound Annual Growth %

	10y	5y	3y
Sales	53.64%	6.77%	(5.83%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(2.99%)	(20.60%)	7.52%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	16	19	—	—	—
’25	13	16	18	16	63
’24	13	15	15	15	58
’23	12	17	35	20	85
’22	24	19	17	16	76
’21	12	18	21	18	69
’20	13	9	9	14	46

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	204	(59)	—	—	—
’25	(20)	(28)	(6)	(13)	(66)
’24	(25)	(22)	(20)	(13)	(80)
’23	(43)	(33)	(17)	(35)	(128)
’22	(47)	(41)	(43)	(48)	(179)
’21	(22)	(34)	(22)	(39)	(117)
’20	(22)	(17)	(24)	(20)	(84)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	204	(59)	—	—	—
’25	(18)	(28)	(6)	(13)	(65)
’24	(25)	(22)	(20)	(28)	(95)
’23	(43)	(35)	(17)	(35)	(130)
’22	(48)	(42)	(64)	(48)	(182)
’21	(22)	(39)	(29)	(42)	(133)
’20	(24)	(20)	(27)	(22)	(91)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	2.82	(0.08)	—	—	—
’25	(0.48)	0.45	0.11	(0.21)	(0.07)
’24	(1.03)	(0.73)	(0.76)	(0.61)	(2.69)
’23	(3.15)	(3.60)	(0.94)	(1.42)	(8.47)
’22	(2.70)	(3.60)	(3.75)	(4.50)	(14.54)
’21	(1.65)	(0.60)	(3.90)	(5.70)	(11.84)
’20	(2.85)	(2.85)	(3.00)	(0.90)	(9.75)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	28.20	32.85	7.35	12.90	15.60	35.40	7.20	1.24	1.36	1.33	Analyst estimates 2026–2028 Powerpack
	High	69.90	76.95	83.10	40.05	71.70	91.50	41.70	17.40	3.07	4.20
People
People	Employees	45	68	88	93	111	173	187	186	101	78
	Revenue/emp, $m	0.37	0.25	0.31	0.39	0.41	0.40	0.41	0.45	0.57	0.81
Income, $m
Income, $m	Revenue	16	17	27	37	46	69	76	85	58	63
	Gross margin, %	95.21	78.79	77.22	71.25	67.99	53.36	59.37	72.91	63.80	66.92
	EBT	(71)	(98)	(131)	(102)	(103)	(164)	(213)	(154)	(121)	(34)
	EBT margin, %	(432.58)	(565.46)	(486.57)	(277.54)	(225.55)	(238.92)	(281.83)	(181.79)	(209.00)	(53.01)
	Net income	(71)	(100)	(142)	(102)	(103)	(165)	(214)	(154)	(121)	(33)
	Depreciation	3	4	4	8	11	11	11	11	9	8
Per share, $
Per share, $	Revenue	6.18	6.21	9.27	10.04	9.49	12.62	12.78	10.42	2.78	2.27
	Earnings	(20.69)	(24.14)	(29.08)	(10.94)	(9.75)	(11.84)	(14.54)	(8.47)	(2.69)	(0.07)
	Cash flow	(17.19)	(29.26)	(34.10)	(26.02)	(17.42)	(21.39)	(30.28)	(15.81)	(3.86)	(2.36)
	Capex	(3.94)	(1.44)	(3.23)	(2.57)	(1.49)	(3.00)	(0.49)	(0.26)	(0.72)	0.04
	Free cash flow	(21.13)	(30.70)	(37.33)	(28.60)	(18.92)	(24.39)	(30.77)	(16.07)	(4.58)	(2.32)
	Book value	31.13	43.37	6.81	19.88	41.02	41.45	8.44	0.20	(0.08)	2.23
	Shares, m	3	3	3	4	5	5	6	8	21	28
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	6.79	9.84	1.39	3.84	5.01	2.97	0.76	0.26	0.73	1.61
	P/B	1.35	1.41	1.89	1.94	1.16	0.90	1.15	13.77	0.00	1.64
	EV/Sales	2.82	5.10	0.55	2.60	1.24	(0.79)	(0.32)	0.13	0.90	1.25
	EV/FCF	(0.82)	(1.03)	(0.14)	(0.90)	(0.62)	0.41	0.12	(0.07)	(0.44)	(0.75)
Cash, $m
Cash, $m	Operating cash flow	(46)	(81)	(99)	(95)	(84)	(117)	(179)	(128)	(80)	(66)
	Capex	(11)	(4)	(9)	(9)	(7)	(16)	(3)	(2)	(15)	1
	Free cash flow	(56)	(85)	(108)	(104)	(91)	(133)	(182)	(130)	(95)	(65)
Balance, $m
Balance, $m	Working capital	53	112	56	111	214	245	103	32	19	74
	Total debt	28	62	80	91	66	47	96	61	58	52
	Net debt	(63)	(68)	(4)	(45)	(167)	(258)	(82)	(20)	1	(27)
	Shareholders’ equity	83	121	20	73	197	226	50	2	(2)	62
Returns, %
Returns, %	ROA	(38.08)	(32.10)	(43.49)	(21.75)	(16.62)	(17.73)	(27.39)	(29.74)	(35.86)	(1.14)
	ROIC	(210.59)	(107.83)	(464.85)	(255.54)	(197.50)	0.00	0.00	0.00	0.00	(124.61)
	ROE	(65.89)	(65.74)	(120.00)	(86.61)	(34.52)	(30.60)	(68.58)	(266.13)	177,428.57	(6.22)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OSTX OS Therapies Incorporated	$66.0M	— (loss-making)	—	—	n/m	−134.43% (below 0%: shrinking)	—	0.00%	Compare
HYFT MindWalk Holdings Corp.	$66.0M	— (loss-making)	— (loss-making)	+19.37% (above 0%: growing)	n/m	+9.79% (above 0%: growing)	58.58%	(159.86%)	Compare
NMAD Nomad Power Solutions, Inc.	$65.9M	— (loss-making)	—	—	n/m	−230.63% (below 0%: shrinking)	—	0.00%	Compare
XBIT XBiotech Inc.	$65.9M	— (loss-making)	— (loss-making)	−93.33% (below 0%: shrinking)	n/m	+25.25% (above 0%: growing)	0.00%	0.00%	Compare
SPRO Spero Therapeutics, Inc.	$65.8M	7.9×	4.2×	−95.61% (below 0%: shrinking)	n/m	+69.73% (above 0%: growing)	100.00%	0.00%	Compare
VRCA Verrica Pharmaceuticals Inc.	$64.9M	— (loss-making)	— (loss-making)	−53.85% (below 0%: shrinking)	n/m	+7.63% (above 0%: growing)	85.02%	(223.42%)	Compare
CING Cingulate Inc.	$63.8M	— (loss-making)	—	—	n/m	−24.28% (below 0%: shrinking)	0.00%	0.00%	Compare
FBIO Fortress Biotech, Inc.	$63.7M	0.6×	1.1×	+14.04% (above 0%: growing)	n/m	−115.37% (below 0%: shrinking)	67.18%	(53.46%)
APLM Apollomics Inc.	$61.2M	— (loss-making)	—	—	0.00%	+76.08% (above 0%: growing)	—	—	Compare
Median of peers	$65.8M	—	—	−73.59%	—	+8.71%	58.58%	0.00%

All 614 Biotechnology stocks →

Fortress Biotech, Inc. (FBIO) key facts

Strength: Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024.
Fortress Biotech, Inc. (FBIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, FBIO traded at $1.87, a market capitalization of $63.7 million.
Return on equity was −6.22% and debt-to-equity 0.17.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −5.47 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.